Editas Medicine, Inc. (EDIT): Free Cash Flow
-$165.85M
Year ended 2025-12-31
-$120.55M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$165.85M | n/m | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | -$219.11M | n/m | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | -$136.90M | n/m | 2025-03-05, From 2023-01-01 |
| 2022-12-31 | -$181.47M | n/m | 2025-03-05, From 2022-01-01 |
| 2021-12-31 | -$171.78M | n/m | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | -$187.00M | n/m | 2023-02-22, From 2020-01-01 |
| 2019-12-31 | -$46.84M | n/m | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | -$50.46M | n/m | 2021-02-26, From 2018-01-01 |
| 2017-12-31 | -$11.48M | n/m | 2020-02-26, From 2017-01-01 |
| 2016-12-31 | -$53.74M | n/m | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | -$6.87M | n/a | 2018-03-08, From 2015-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | -$165.85M | n/m |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | -$135.06M | n/m |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | -$97.31M | n/m |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | -$234.34M | n/m |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | -$99.30M | n/m |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | -$85.62M | n/m |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | -$65.93M | n/m |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | -$13.63M | n/m |
| Invivyd, Inc. (IVVD) | 2025-12-31 | -$58.29M | n/m |
Compare EDIT, VYGR, SGMOQ, KYMR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗